Provides relative to kratom (EG INCREASE SG EX See Note)
HB 253 creates the “Kratom Consumer Protection Act” and adds a new Chapter 9 to Title 26 of the Louisiana Revised Statutes governing kratom products. The bill defines key terms such as kratom leaf, kratom leaf extract, kratom product, vendor, and total kratom alkaloids, and then sets product standards that kratom items must meet before they may be manufactured, distributed, or sold in Louisiana.
The bill prohibits kratom products containing unsafe substances, artificial alkaloids, excessive 7-hydroxymitragynine, excessive residual solvents, or other chemical profiles that do not meet the bill’s requirements. It also bars liquid kratom products that do not clearly identify serving size and prohibits products that are not registered with the Louisiana Department of Health (LDH). In addition, manufacturers must register each product annually, pay a registration fee, and submit a certificate of analysis from a U.S.-based testing facility to verify compliance.
HB 253 also imposes labeling requirements. Kratom products must list ingredients, disclose that sales to persons under 21 are prohibited, identify alkaloid content, provide the vendor’s name and address, include allergen and safe-use information, and carry warnings about habit-forming potential and the lack of FDA-approved therapeutic claims. Vendors must provide test results to LDH upon request, and processors must report adverse events to LDH and the FDA; failure to report can lead to revocation of a product’s registration.
The bill’s impact is to establish a state regulatory framework for kratom similar to consumer-protection and product-safety regimes used for other ingestible products. It would give LDH oversight over product registration, testing, labeling, and adverse-event reporting, while restricting sales of kratom products that do not meet chemical, packaging, or disclosure standards. Manufacturers, processors, vendors, and retailers handling kratom would be directly affected, and products failing to comply could be denied registration or removed from the market.
The available context shows generally regulatory and consumer-safety-oriented intent, with no recorded opposition in the provided transcripts or vote history. The bill appears designed to standardize kratom sales and reduce youth access and unsafe formulations rather than ban kratom outright. The main points of potential contention are likely to be the scope of state regulation, the registration fee and testing burden on manufacturers, the product-composition limits, and the requirement for adverse-event reporting and LDH oversight.
HB 253 would add R.S. 26:941 through 944 to the Louisiana Revised Statutes and create a new regulatory chapter for kratom products under Title 26. It would authorize the Louisiana Department of Health to register kratom products, collect fees, review certificates of analysis, refuse registration for noncompliant products, and revoke registrations for failure to report adverse events. The bill would also impose new labeling, testing, and product-composition requirements on kratom manufacturers, processors, vendors, and retailers, while prohibiting sales to persons under 21.
Based on the bill text and the limited context provided, the overall sentiment appears supportive of consumer protection and product safety. The measure is framed as a regulatory approach to kratom rather than a prohibition, suggesting an effort to balance access with oversight. No committee transcript or vote record was provided showing organized opposition or debate, so the available record does not indicate strong controversy in the materials supplied.
The most likely areas of contention are the bill’s detailed chemical restrictions, the annual registration requirement, and the administrative and testing costs imposed on manufacturers and vendors. Stakeholders in the kratom industry may object to the limits on alkaloid content, the ban on artificial compounds, the residual-solvent standards, and the requirement that products be registered with LDH before sale. Consumer-safety advocates, by contrast, would likely support the age restriction, labeling warnings, and adverse-event reporting requirements as necessary safeguards.